• “Time to Clinical Benefit of Sotagliflozin in People with Worsening Heart Failure in SOLOIST-WHF”, a moderated poster presentation on Saturday, March 4th at 11:00 am CT
• “Effects of SGLT 1-2 Inhibitor Sotagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients with Worsening Heart Failure: Results from the SOLOIST Trial”, a moderated poster presentation on Saturday, March 4th at 10:15 am CT
• “Levels of Soluble Urokinase Plasminogen Activator Receptor and Heart Failure Outcomes in Patients with Type 2 Diabetes and Worsening Heart Failure Treated with Sotagliflozin, a Dual SGLT 1 and SGLT 2 Inhibitor”, a poster presentation on Sunday, March 5th at 2:45 pm CT
• “Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Modulated Expression of Atheroprotective Proteins during Inflammation Compared with Empagliflozin”, a moderated poster presentation on Monday, March 6th at 10:30 am CT